IMPACT BIOMEDICAL INC. (IBO) Profit Margins
Over the twelve months to 2026-06-30, IMPACT BIOMEDICAL INC. (IBO) had operating margin -14597.1%, net margin 2254.3%, free cash flow margin -1451.4%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IBOIMPACT BIOMEDICAL INC.Follow IBO — free
—
Price chart with a free account
- Market cap
- 30.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 13 days
| Line | FY2022 Dec 22 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Gross margin | — | -1225.0% | — | |
| Operating margin | — | -13381.3% | -14597.1% | |
| Net margin | — | -36993.8% | 2254.3% | |
| FCF margin | — | -5906.3% | -1451.4% |
USD millions · SEC XBRL
IMPACT BIOMEDICAL INC. — questions
- What is IMPACT BIOMEDICAL INC.'s operating margin?
- -14597.1% over the twelve months to 2026-06-30.
- What is IMPACT BIOMEDICAL INC.'s net profit margin?
- 2254.3% over the twelve months to 2026-06-30.
Every figure on this page comes from IMPACT BIOMEDICAL INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.